• In the first quarter of 2026, Merit Medical Systems reported sales of US$381.88 million and net income of US$41.00 million, and it raised full-year 2026 revenue guidance to a range of US$1.61 billion–US$1.63 billion.
• Alongside these results, mixed insider activity, with a director selling shares and senior executives buying through 401(k) plans, offers a nuanced view of internal confidence.
• With Merit lifting its full-year revenue outlook, we will now examine how this guidance upgrade affects the company’s investment narrative.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical Systems, you need to believe its diversified device portfolio can keep converting procedure demand into steady revenue and earnings, despite cost and regulatory pressures. The latest Q1 beat and slightly higher 2026 revenue guidance appear supportive, but do not remove key near term risks around product quality events and reimbursement timing for newer therapies, which remain central to the story.

The Q1 2026 earnings release, with sales of US$381.88 million and net income of US$41.00 million, is the most relevant update here because it underpins the revised 2026 revenue outlook of US$1.61 billion to US$1.63 billion. That guidance now sits against ongoing recall activity in renal products and higher tariffs, which could influence how much of this upgraded top line target ultimately flows through to margins and earnings.

Yet behind these stronger numbers, investors should also be aware of the risk that...

Merit Medical Systems' narrative projects $1.8 billion revenue and $197.1 million earnings by 2029. This requires 6.4% yearly revenue growth and about a $68.6 million earnings increase from $128.5 million today.

Uncover how Merit Medical Systems' forecasts yield a $98.36 fair value, a 57% upside to its current price.

Exploring Other Perspectives

The lowest estimate analysts paint a tougher picture for you, even before this news, assuming only about US$1.8 billion revenue and US$210.1 million earnings by 2029 while worrying more about tariff pressure and logistics disruptions.

Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth just $95.28!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merit Medical Systems research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.